Search results
Author(s):
John Forrest
Added:
1 year ago
ACC.23/WCC - We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial(Medtronic Cardiovascular) (NCT02701283).
This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis…
View more
Author(s):
Nicolas M Van Mieghem
,
Michael J Reardon
Added:
4 years ago
Prof Michael J Reardon (Houston Methodist, Texas, US) and Dr Nicolas van Mieghem (Rotterdam, NL) discuss the corevalve low-risk TAVR trial - self-expanding transcatheter or surgical aortic valve replacement in patients at low risk of surgical mortality.
Filmed on site at ACC 2019 by Radcliffe Cardiology.
Videography: Josh Birch
Educational lead: Liam O'Neill (Chief Operating Officer)
View more
Author(s):
Toby Rogers
Added:
3 years ago
In this video, Dr Toby Rogers (MedStar Washington Hospital Center, Washington DC, US) talks about Transcatheter Aortic Valve Replacement in low-risk patients with bicuspid aortic stenosis, presenting the results of the LRT Trial. This study aims to evaluate the transcatheter heart valve haemodynamics in low-risk patients one year after TAVR.
Recorded remotely from Washington, 2021.
Editor:…
View more
Author(s):
Nicolas M Van Mieghem
Added:
6 years ago
In this video, Dr Nicolas Van Mieghem discusses the question; 'are we ready to be doing TAVR in low risk patients?'.
View more
TCT 23: EVOLUT Low-Risk
Author(s):
Michael J Reardon
Added:
5 months ago
Video
Author(s):
Martin B Leon
Added:
4 months ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic…
View more
Author(s):
David J Cohen
Added:
2 years ago
Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up.
Discussion Points
Importance of the Study
Used Data
Complexities in Relation to the Costs of…
View more
Author(s):
Raj Makkar
Added:
2 years ago
In this interview, Dr Raj Makkar (Cedars-Sinai Medical Center, Los Angeles, CA, US) discusses the Transcatheter Aortic Valve Replacement for bicuspid aortic stenosis in a patient population with low risk for surgery.
Questions:
What is the rationale for this study?
Describe the design, patient population and endpoints?
What are the key findings and what conclusions can be made?
Which patients…
View more
TCT 2023 Late-Breaking Science Collection
Author(s):
Giovanni Luigi Di Maria
,
Samir R Kapadia
,
Matthias Gotberg
Added:
2 months ago
Video Series
Added:
5 months ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more